Cover Image
市場調查報告書

Progen Pharmaceuticals Limited:產品平台分析

Progen Pharmaceuticals Limited - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 251709
出版日期 內容資訊 英文 31 Pages
訂單完成後即時交付
價格
Back to Top
Progen Pharmaceuticals Limited:產品平台分析 Progen Pharmaceuticals Limited - Product Pipeline Review - 2015
出版日期: 2015年12月23日 內容資訊: 英文 31 Pages
簡介

Progen Pharmaceuticals Limited是進行癌症治療藥的藥物之研究、開發的生物科技企業。

本報告提供Progen Pharmaceuticals Limited的治療藥開發平台現狀及各開發階段的比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,彙整最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

Progen Pharmaceuticals Limited的基本資料

Progen Pharmaceuticals Limited概要

  • 主要資訊
  • 企業資料

Progen Pharmaceuticals Limited:R&D概要

  • 主要的治療範圍

Progen Pharmaceuticals Limited:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Progen Pharmaceuticals Limited:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Progen Pharmaceuticals Limited:藥物簡介

  • muparfostat
  • PG-11047
  • PG-545
  • PG-11000系列
  • PG-11100系列
  • PG-11144
  • PG-11157
  • PG-11158
  • PG-11159
  • PG-11160
  • 主要治療用以HDAC及LSD-1為目標的小分子
  • 主要治療用以Hheparanaze為目標的小分子
  • 主要治療用以LSD-1為目標的小分子

Progen Pharmaceuticals Limited:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Progen Pharmaceuticals Limited:最近的開發平台趨勢

Progen Pharmaceuticals Limited:暫停中的計劃

Progen Pharmaceuticals Limited:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • PG-562
    • muparfostat

Progen Pharmaceuticals Limited:企業發表

Progen Pharmaceuticals Limited:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07916CDB

Summary

Global Markets Direct's, 'Progen Pharmaceuticals Limited - Product Pipeline Review - 2015', provides an overview of the Progen Pharmaceuticals Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Progen Pharmaceuticals Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Progen Pharmaceuticals Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Progen Pharmaceuticals Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Progen Pharmaceuticals Limited's pipeline products

Reasons to buy

  • Evaluate Progen Pharmaceuticals Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Progen Pharmaceuticals Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Progen Pharmaceuticals Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Progen Pharmaceuticals Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Progen Pharmaceuticals Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Progen Pharmaceuticals Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Progen Pharmaceuticals Limited Snapshot
    • Progen Pharmaceuticals Limited Overview
    • Key Information
    • Key Facts
  • Progen Pharmaceuticals Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Progen Pharmaceuticals Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Progen Pharmaceuticals Limited - Pipeline Products Glance
    • Progen Pharmaceuticals Limited - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Progen Pharmaceuticals Limited - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Progen Pharmaceuticals Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Progen Pharmaceuticals Limited - Drug Profiles
    • muparfostat sodium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PG-545
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Target Heparanase for Oncology, Immunology and Diabetes
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Progen Pharmaceuticals Limited - Pipeline Analysis
    • Progen Pharmaceuticals Limited - Pipeline Products by Target
    • Progen Pharmaceuticals Limited - Pipeline Products by Route of Administration
    • Progen Pharmaceuticals Limited - Pipeline Products by Molecule Type
    • Progen Pharmaceuticals Limited - Pipeline Products by Mechanism of Action
  • Progen Pharmaceuticals Limited - Recent Pipeline Updates
  • Progen Pharmaceuticals Limited - Dormant Projects
  • Progen Pharmaceuticals Limited - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • PG-562
  • Progen Pharmaceuticals Limited - Company Statement
  • Progen Pharmaceuticals Limited - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Progen Pharmaceuticals Limited, Key Information
  • Progen Pharmaceuticals Limited, Key Facts
  • Progen Pharmaceuticals Limited - Pipeline by Indication, 2015
  • Progen Pharmaceuticals Limited - Pipeline by Stage of Development, 2015
  • Progen Pharmaceuticals Limited - Monotherapy Products in Pipeline, 2015
  • Progen Pharmaceuticals Limited - Phase III, 2015
  • Progen Pharmaceuticals Limited - Phase I, 2015
  • Progen Pharmaceuticals Limited - Preclinical, 2015
  • Progen Pharmaceuticals Limited - Discovery, 2015
  • Progen Pharmaceuticals Limited - Pipeline by Target, 2015
  • Progen Pharmaceuticals Limited - Pipeline by Route of Administration, 2015
  • Progen Pharmaceuticals Limited - Pipeline by Molecule Type, 2015
  • Progen Pharmaceuticals Limited - Pipeline Products by Mechanism of Action, 2015
  • Progen Pharmaceuticals Limited - Recent Pipeline Updates, 2015
  • Progen Pharmaceuticals Limited - Dormant Developmental Projects,2015
  • Progen Pharmaceuticals Limited - Discontinued Pipeline Products, 2015
  • Progen Pharmaceuticals Limited, Subsidiaries

List of Figures

  • Progen Pharmaceuticals Limited - Pipeline by Top 10 Indication, 2015
  • Progen Pharmaceuticals Limited - Pipeline by Stage of Development, 2015
  • Progen Pharmaceuticals Limited - Monotherapy Products in Pipeline, 2015
  • Progen Pharmaceuticals Limited - Pipeline by Top 10 Target, 2015
  • Progen Pharmaceuticals Limited - Pipeline by Top 10 Route of Administration, 2015
  • Progen Pharmaceuticals Limited - Pipeline by Top 10 Molecule Type, 2015
  • Progen Pharmaceuticals Limited - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top